Dear Editor,

The aberrant activation of the PI3K/AKT pathway in melanoma is known to be caused by genomic deletion, promoter methylation or loss-of-function mutations of phosphatase and tensin homolog on chromosome 10 (PTEN) (see ref. ([@R10]) for a review).

More recently, PTEN protein abundance was shown to be decreased at the post-transcriptional level by a complex microRNA network ([@R7]).

The processed pseudogene of *PTEN*, *PTENP1*, is a modulator of the interaction between *PTEN* mRNA and *PTEN*-targeting microRNAs ([@R12]). *PTENP1* shows extensive sequence similarity with *PTEN*. The high level of conservation in the most upstream region of the 3'UTR allows *PTENP1* mRNA to be bound by many of the microRNA families that bind *PTEN* mRNA ([Figure 1](#F1){ref-type="fig"} and [Supplemental Text S1](#SD1){ref-type="supplementary-material"}). Therefore, *PTENP1* can protect *PTEN* from microRNA-mediated downregulation. Consistent with its activity as a decoy for *PTEN*-targeting microRNAs, *PTENP1* is a *bona fide* tumor suppressor gene that causes growth inhibition in prostate cancer cells and undergoes deletion in various human malignancies ([@R12]).

As recently pointed out ([@R4]), the post-transcriptional regulation of PTEN levels in melanoma has not been studied yet and the status of *PTENP1* on 9p13 is unknown. Here, we report the analysis of *PTENP1* locus in human melanoma cell lines and tissues ([Table S1](#SD1){ref-type="supplementary-material"}). We also analyze the relationship between: 1) *PTENP1* deletion and *CDKN2A* deletion, as they are located approximately 20cM apart on chromosome 9p ([@R2]); 2) *PTENP1* deletion and *PTEN* deletion, as 9p and 10q losses often coexist in melanoma ([@R9]); 3) *PTENP1* deletion and BRAF/NRAS mutation, as the combination of mutated BRAF (but not NRAS) and loss of *PTEN* expression is a common event in human melanoma ([@R13]).

Our genomic analysis revealed partial deletion of *PTENP1* locus in 14.3% of the cell lines tested ([Figure 2a](#F2){ref-type="fig"}). In addition, *PTENP1* was found to be deleted in 20.9% of melanoma tissues (8 partial and 1 complete deletion) ([Figure 2b](#F2){ref-type="fig"}). These results illustrate that *PTENP1* is under selective pressure to undergo copy number losses ([@R12]). The average PTEN expression level in the 9 samples with either partial or complete deletion of *PTENP1* (P5, P9, P11, P12, P20, M1, M9, M14 and M16) was lower than in the remaining 34 samples without any *PTENP1* deletion (5.22 ± 2.30 N=9 vs. 20.59 ± 3.98 N=34, p = 0.06), confirming the protective effect of *PTENP1* on PTEN levels ([@R12]).

The details of the analyses of *CDKN2A* deletion, *PTEN* deletion, and BRAF and NRAS mutation in the human melanoma cell lines and tissues are provided in [Supplemental Text S2](#SD1){ref-type="supplementary-material"}.

We observed that the partial or complete deletion of *PTENP1* is always concomitant with the partial or complete deletion of *CDKN2A* in human melanoma cell lines, but not in human melanoma tissues. The "focal" deletion of *PTENP1* (5/9 cases) has already been reported in other cancer types, such as breast and colon cancer ([@R12]), but is particularly interesting in melanoma, because it happens in spite of the fact that *CDKN2A* deletions are the most common alterations ([@R2]).

As far as the relationship between the partial or complete deletion of *PTENP1* and that of *PTEN* is concerned, we observed that *PTEN* is deleted in 7/9 melanoma tissues that show *PTENP1* deletion ([Figure 2b](#F2){ref-type="fig"}). This result is supported by previous loss-of-heterozygosity analyses ([@R8]) and is in agreement with the observation that 9p and 10q losses often coexist in melanoma ([@R9]).

The co-deletion of *PTEN* and *PTENP1* can be reconciled with the function of *PTENP1* as decoy for *PTEN*-targeting microRNAs. *PTEN* deletion, either partial or complete, was found in 23 melanoma tissues. Excluding the cases in which *PTEN* deletion is complete and therefore *PTENP1* deletion cannot affect PTEN levels, on average we observed lower PTEN protein expression in the samples showing both *PTEN* partial deletion and *PTENP1* deletion compared to those showing *PTEN* partial deletion only, as exemplified by P5 and M5 tissues in [Figure 2b](#F2){ref-type="fig"}. In the context of partial *PTEN* deletion, *PTENP1* deletion may cause a further decrease in PTEN levels, possibly due to less efficient sheltering of *PTEN*-targeting microRNAs. Of note, *PTENP1* deletion may also affect PTEN levels when PTEN is downregulated by mechanisms other than genomic deletion, such as inactivating mutations.

The biological effects of *PTENP1* deletion are likely to be particularly strong on PTEN because of the intrinsic nature of this haploinsufficient tumor suppressor whose variations of even 20% can have profound consequences on cancer onset and progression ([@R3]). Nonetheless, the concomitant deletion of *PTENP1* and *PTEN* points towards *PTEN*-independent functions of *PTENP1* as well. Two possible explanations can be invoked. First, *PTENP1* is likely to function as decoy for additional microRNA families which are not *PTEN*-targeting. These microRNAs should preferentially bind to the R2 region of the 3'UTR that shows low homology with the corresponding one on *PTEN* ([Figure 1a](#F1){ref-type="fig"}) and might affect targets that belong to other signaling cascades, so that the concomitant deletion of *PTENP1* and *PTEN* causes the activation of independent pathways that possibly cooperate in tumorigenesis. Second, the *PTEN*-targeting microRNAs for which *PTENP1* acts as decoy have additional targets. Therefore, the deletion of *PTENP1* might be advantageous for the tumor because of the decrease of other oncosuppressor genes besides PTEN ([@R12]).

Examples of these genes are BIM, p21 and Sprouty2. The pro-apoptotic factor BIM is a miR-17 family-target ([@R6]). Mutant BRAF and NRAS induce the MAPK-dependent phosphorylation and consequent proteosomal degradation of BIM in order to provide melanoma cells with resistance to anoikis ([@R1]). The CDK inhibitor p21, another target of miR-17 family ([@R6]), is repressed transcriptionally by TBX2 and TBX3 transcription factors which are frequently amplified in melanoma and are downstream effectors of the MAPK pathway ([@R2]). Sprouty2 is a *wt* BRAF inhibitor that is targeted by miR-21. The downregulation of Sprouty2 observed in melanoma has been hypothesized as an alternative mechanism responsible for the aberrant activation of MAPK pathway besides BRAF mutation ([@R14]). Of note, the three genes described above share a common feature as antagonists of the MAPK pathway. Since the PI3K/AKT and the MAPK pathways have been shown to cooperate in melanomagenesis both *in vitro* and in mouse models ([@R5]; [@R11]), it is tempting to hypothesize that, in the context of *PTEN* deletion, the deletion of *PTENP1* might be an alternative mechanism evolved by the tumor to activate the MAPK pathway. In this respect, it is worth noticing that most of the cases showing both *PTENP1* and *PTEN* deletion (71.4%) harbor *wt* BRAF.

In conclusion, our data indicate that the recently identified tumor suppressor gene *PTENP1* undergoes genomic deletion in human melanoma. Our data also suggest that *PTENP1* deletion might be advantageous for the tumor not only because of its *PTEN*-related function, but also for *PTEN*-unrelated ones.
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![*PTEN*- and *PTENP1*-targeting microRNAs\
**a.** Schematic representation of *PTEN* and *PTENP1* 3'UTR. The most upstream region of the 3'UTR (R1, dark grey) is highly conserved between *PTEN* and *PTENP1*. In the middle R2 region (light grey), the conservation drops dramatically. The downstream R3 region (white) is present only in *PTEN* (modified from [@R12]). **b.** List of the *PTEN*-targeting microRNA families validated so far. The region of the 3'UTR where the microRNA binding sites are located and the conservation of these sites in *PTENP1* 3'UTR are indicated. Out of a total of 18 *PTEN*-targeting microRNA families, 12 are *PTENP1*-targeting as well (grey). All these families have at least 1 binding site in the high homology R1 region.](nihms-309837-f0001){#F1}

![Analysis of *CDKN2A*, *CDKN2B*, *MTAP*, *PTENP1*, *PTEN*, BRAF and NRAS status in human melanoma cell lines (a) and tissues (b)\
**a.** 14 primary (WM series) and 14 metastatic (Sk-Mel series, 501Mel, A375 and 451Lu) melanoma cell lines and **b.** 23 primary (P1-P23) and 20 metastatic (M1-M20) melanoma tissues were analyzed by qPCR on genomic DNA to identify deletions at 9p21 (*CDKN2A*, *CDKN2B* and *MTAP* loci), 9p13 (*PTENP1* locus) and 10q (*PTEN* locus). Mutations identified in exon 11 and 15 of BRAF and exon 2 and 3 of NRAS are reported. PTEN protein levels were analyzed in melanoma tissues by immunohistochemistry (IHC) and the percentage of positive cells is indicated. N/A: genomic qPCR not performed due to constraints on DNA availability. On the left, IHC shows lower PTEN levels in P5 tissue harboring partial *PTEN* and *PTENP1* deletion compared to M5 tissue harboring partial *PTEN* deletion only.](nihms-309837-f0002){#F2}
